Short-term influence of Immufen™ on mild allergic rhinitis: a randomized, double-blind, placebo-controlled study.
| Autor: | K M; Department of General Medicine, Divakar's Specialty Hospital, Bengaluru, India., Aryan MK; Department of Immunology, Amala Cancer Research Centre, Thrissur, India., Prabhakaran P; R&D Centre, Akay Natural Ingredients, Kochi, India., Mulakal JN; R&D Centre, Akay Natural Ingredients, Kochi, India., Das S S; R&D Centre, Akay Natural Ingredients, Kochi, India., Im K; R&D Centre, Akay Natural Ingredients, Kochi, India., Parameswara Panicker S; Department of Zoology, Advanced Centre for Regenerative Medicine and Stem Cell Research in Cutaneous Biology (AcREM-STEM), University of Kerala, Kariavattom, Thiruvananthapuram, India. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in allergy [Front Allergy] 2024 Oct 14; Vol. 5, pp. 1390813. Date of Electronic Publication: 2024 Oct 14 (Print Publication: 2024). |
| DOI: | 10.3389/falgy.2024.1390813 |
| Abstrakt: | Introduction: Allergic rhinitis (AR) is an IgE-mediated reaction to inhaled allergens, and is a prominent health concern affecting approximately 400 million people worldwide. A comprehensive understanding of AR's pathophysiology is imperative for developing novel therapies, especially considering its frequent co-morbidity with asthma and conjunctivitis. The escalating prevalence of AR is correlated with increased urbanization and environmental pollutants, recognized as prominent contributing factors. Dysregulation in immune networks, Th1/Th2 cytokine imbalance, activation of mast cells and eosinophils are implicated in AR progression. Classic AR symptoms include nasal congestion, nasal itching, rhinorrhea, and sneezing which significantly impact the quality of life, social interactions, and workplace productivity. Methods: This randomized, double-blind, placebo-controlled, three-arm, three-sequence study was aimed to assess the efficacy of supplementation of a co-delivery form of turmeric extract with ashwagandha extract (CQAB) in comparison with a bioavailable curcumin (CGM) and placebo in alleviating AR symptoms and enhancing the quality of life in individuals with mild AR. Participants received either placebo, CGM, or CQAB twice/day for 28 days, and subjective measures were recorded at the baseline and at the end of study. Results: CQAB supplementation demonstrated a significant ( P < 0.05) improvement in Total Nasal Symptom Score (TNSS) compared to placebo and CGM. Furthermore, CQAB administration resulted in enhanced sleep quality ( P < 0.05) as evaluated by the BIS questionnaire, heightened energy levels, and decreased fatigue and overall mood disturbance (POMS-SF) compared to both placebo and CGM. Conclusion: The results suggests that CQAB has the potential to be used as a dietary supplement in alleviating AR discomforts. Clinical Trial Registration: https://ctri.nic.in/Clinicaltrials/login.php; Identifier CTRI/2021/01/030355. Competing Interests: The authors declare that this study received funding from Akay Natural Ingredients. PP, JM, SD and KIM were employed by Akay Natural Ingredients. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (© 2024 K, Aryan, Prabhakaran, Mulakal, Das S, IM and Parameswara Panicker.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|